Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study Evaluating the Efficacy and Tolerability of Dolutegravir Plus Lamivudine in HIV Infected Adults Who Are Virologically Suppressed and With Evidence of TDF Toxicity

NCT05493969 is registered in ClinicalTrials.gov with Shanghai Public Health Clinical Center as lead sponsor.

NCT NCT05493969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05493969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study Evaluating the Efficacy and Tolerability of Dolutegravir Plus Lamivudine in HIV Infected Adults Who Are Virologically Suppressed and With Evidence of TDF Toxicity
Lead sponsor
Shanghai Public Health Clinical Center
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2022
Completion date
June 30, 2026
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acquired immunodeficiency syndrome